Will Bausch + Lomb break free from debt-heavy Bausch Health? Sale rumours ignite market frenzy!

Will Bausch + Lomb break free from debt-heavy Bausch Health? Sale rumours ignite market frenzy!

Bausch + Lomb saw its stock surge by 13% in Toronto, trading at 24.01 Canadian dollars (around $17.67), following a report by the Financial Times suggesting the eye care company is considering a sale. The possible sale is being considered as a way to separate from its heavily indebted parent company, Bausch Health Companies Inc. […]

Lupin subsidiary MedQuímica buys rights to nine drugs from Bausch Health

Lupin subsidiary MedQuímica buys rights to nine drugs from Bausch Health

Lupin Limited said that MedQuímica Indústria Farmacêutica, its 100% subsidiary in Brazil, has agreed to acquire all rights to nine drugs from Bausch Health Companies’ subsidiary BL Indústria Ótica. The financial terms of the deal were not disclosed. Through the deal, MedQuímica will gain rights to the three central nervous system drugs — Limbitrol, Melleril, […]

Glenmark gets marketing approval for Ryaltris in 13 European countries

Glenmark gets marketing approval for Ryaltris in 13 European countries

Glenmark Pharmaceuticals said that it has secured marketing approval for Ryaltris, a fixed-dose combination nasal spray, in 13 countries across the European Union (EU) and the UK. Ryaltris (olopatadine 665 µg and mometasone furoate 25 µg) has approval for the symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children, aged over 12. […]